Study: Cannabis Agonists Produce Anti-Cancer Effects In Human Liver Cancer Cells.
Tehran, Iran: The administration of
synthetic cannabinoid agonists reduce cell viability in human
hepacarcinoma cells and may be a potential option for the treatment
of liver cancer, according to preclinical data published online in the journal Toxicology
Mechanisms and Methods.
Investigators from the Tehran University of Medical Sciences,
Department of Toxicology and Pharmacology assessed the anti-cancer
properties of two synthetic cannabinoids, CB65 (CB2 receptor
agonist) and ACEA (CB1 receptor agonist) in human hepacarcinoma
cells.
Authors reported that the administration of cannabinoids reduced
malignant cell viability and cell invasion in a dose-dependent
manner. "These data suggest ACEA and CB65 as an option for novel
treatment of hepatocellular cancer," they concluded.
Previous
studies have demonstrated that cannabinoids inhibit tumor cell
growth and selectively induced apoptosis by different cell
signaling pathways in various types of malignant cells, including
gliomas (brain cancers) and lymphomas, prostate, breast, lung,
skin, and pancreatic cancer cells.
For more information, please contact Paul Armentano, NORML
Deputy Director, at: paul@norml.org. Full text
of the study, "Evaluation of Anti-invasion Effect of
Cannabinoids on Human Hepatocarcinoma Cells," is available in
Toxicology Mechanisms and Methods.
No comments:
Post a Comment